Dr Enriqueta Felip, head of the Thoracic Tumours and Head and Neck Cancer Group at VHIO and section head in…
featured news home
After an initial response to approved tyrosine kinase inhibitors, principally imatinib, most patients with GIST will develop acquired cancer drug…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
The five-year follow up data from patients in the KEYNOTE-048 trial have been reported, with the participation of Dr. Irene…
Results of long-term survival analysis of the phase III EMPOWER-Cervical 1 multicenter clinical trial show that immune checkpoint inhibitor cemiplimab…
Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led…
Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded…
Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies…
The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
